Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.5K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.5K
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

64
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The...
64
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

721
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
721
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

75
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
75
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

79
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows...
79
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

61
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
61

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Twenty-One Years of Insights From A Single-Center Living Kidney Donation Program.

Transplantation proceedings·2026
Same author

Counterfactual evaluation of elementary and secondary school policies in the COVID-19 pandemic.

Nature communications·2026
Same author

Immune Checkpoint Inhibitor-Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal Implant: Clinical Outcomes in a Retrospective Case-Series.

Ocular immunology and inflammation·2026
Same author

Diagnostic pitfall in MBD4-associated neoplasia syndrome after hematopoietic stem cell transplantation.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026
Same author

Paraneoplastic Pemphigus and Liver Biopsy Needle Track Dissemination in Hepatocellular Carcinoma: A Case Report.

GE Portuguese journal of gastroenterology·2026
Same author

A modified Delphi consensus on periprosthetic infection in orthopaedic oncology : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2025

Related Experiment Video

Updated: May 7, 2026

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
12:37

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

Published on: September 11, 2012

46.8K

Ibandronate-associated ischemic colitis: case report.

Sofia Vitor, Ana Nunes, Cristina Fonseca

    Acta Reumatologica Portuguesa
    |October 16, 2013
    PubMed
    Summary
    This summary is machine-generated.

    Ibandronate, a bisphosphonate drug, may cause colon bleeding and sigmoid ischemia, a rare side effect not previously reported in humans. Withdrawal of the medication led to complete recovery.

    More Related Videos

    Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
    04:05

    Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

    Published on: May 31, 2024

    1.1K
    Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
    08:34

    Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

    Published on: July 27, 2022

    1.1K

    Related Experiment Videos

    Last Updated: May 7, 2026

    Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
    12:37

    Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

    Published on: September 11, 2012

    46.8K
    Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
    04:05

    Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

    Published on: May 31, 2024

    1.1K
    Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
    08:34

    Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

    Published on: July 27, 2022

    1.1K

    Area of Science:

    • Gastroenterology
    • Pharmacology

    Background:

    • Ibandronate is a widely used bisphosphonate for osteoporosis treatment.
    • Gastrointestinal side effects are typically limited to the upper tract.

    Observation:

    • A 52-year-old female experienced recurrent lower abdominal pain after oral ibandronate administration.
    • The second episode was associated with hematochezia, sigmoid colonoscopy revealing ischemic changes.

    Findings:

    • Endoscopic and histological examination confirmed sigmoid ischemia.
    • No alternative causes for ischemic colitis were identified.
    • This represents the first documented case of colon bleeding linked to ibandronate use.

    Implications:

    • This case suggests a potential association between oral ibandronate and large bowel ischemia.
    • Clinicians should consider ibandronate as a possible cause of ischemic colitis in patients presenting with relevant symptoms.
    • Further research may be warranted to elucidate the mechanism and incidence of this rare adverse event.